MSI-H
About
Biomarker Type: Microsatellite Stability
Present: True
Status: Microsatellite instability-high (MSI-H)
Legacy biomarker representation, assumes GRCh37 / hg19 genome build.
Mappings
Therapeutic response
Precision oncology relationships for therapeutic response involving this biomarker.
| Organization(s) | Biomarker(s) | Cancer type | Therapy(ies) | |
|---|---|---|---|---|
| EMA (1) FDA (1) | MSI-H | Endometrial Carcinoma | Carboplatin, Dostarlimab, Paclitaxel | |
| EMA (4) FDA (2) | MSI-H | Colorectal Adenocarcinoma | Ipilimumab, Nivolumab | |
| FDA (1) | MSI-H | Any solid tumor | Pembrolizumab | |
| EMA (1) FDA (1) | MSI-H | Colorectal Adenocarcinoma | Pembrolizumab | |
| EMA (1) FDA (1) | MSI-H | Endometrial Carcinoma | Pembrolizumab | |
| FDA (1) | MSI-H | Colorectal Adenocarcinoma | Nivolumab | |
| EMA (1) | MSI-H | Endometrial Carcinoma | Dostarlimab | |
| EMA (1) | MSI-H | Esophagogastric Adenocarcinoma | Pembrolizumab | |
| EMA (1) | MSI-H | Gastrointestinal Stromal Tumor | Pembrolizumab | |
| EMA (1) | MSI-H | Cholangiocarcinoma | Pembrolizumab |